Engflag

Adenosylcobalamin

Quick links to important sections

Adenosylcobalamin

Adenosylcobalamin_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adenosylcobalamin

Property Description
Active Ingredient Adenosylcobalamin (AdoCbl), also known as Dibencozide
Form Typically Injection solution, oral capsules, or tablets
Pharmacological Class Vitamin B12 derivative, Hematopoietic agent
Common Use Replenishment of the bioactive B12 coenzyme
Origin Endogenous coenzyme form (natural in human tissues)

Adenosylcobalamin: Definition, Class, and Identity

Adenosylcobalamin (AdoCbl) is defined as one of the two endogenous (natural) and bioactive coenzyme forms of Vitamin B12 (Cobalamin) found within the human body. Its classification as a Vitamin B12 derivative and a Hematopoietic agent supports processes essential for blood formation. The compound is also chemically recognized as 5'-deoxyadenosylcobalamin and commercially by the synonym Dibencozide. This differentiates it from synthetic precursors, as it provides the necessary complex molecule directly to the tissues, bypassing the metabolic steps required for non-coenzyme forms.

The Bioactive Form and Compositional Difference

Adenosylcobalamin is the principal bioactive form of Cobalamin utilized inside the cell's mitochondria, where it acts as a cofactor for the enzyme Methylmalonyl-CoA mutase. This unique mitochondrial role is vital for specific metabolic pathways. This single-ingredient product is typically delivered as an injection solution (parenteral route) for immediate systemic availability, or in oral capsules, tablets, and specialized sublingual forms. This variety in dosage form is a key differentiating factor, making the active coenzyme accessible to various patient groups, including those with malabsorption issues.

General Purpose: Why Use the Active Coenzyme?

The general purpose of administering Adenosylcobalamin is to replenish the body's reserve of the active coenzyme, ensuring the proper function of cellular metabolism at a fundamental level. By providing this already active form, the substance helps support the internal processes involved in the efficient breakdown and utilization of fats and proteins for energy. This action helps maintain the necessary foundation for B12-dependent enzyme function, often used in scenarios requiring robust metabolic support.

What side effects are possible with Adenosylcobalamin?

Possible Side Effects and Safety Information

The officially documented safety characteristics and potential adverse effects of Adenosylcobalamin (Cobalamin class) are defined by government regulatory standards, focusing on established risks associated with parenteral and high-dose B12 preparations.

Documented Adverse Reactions and Systemic Patterns

Adverse reactions are classified by the physiological system or organ group affected as listed in regulatory labeling:

  • Dermatological Reactions: Documented effects include conditions involving the skin, such as pruritus (itching), transitory exanthema (rash), acne, or rosacea.
  • Gastrointestinal Disturbances: Safety data lists mild transient diarrhea as a possible reaction, along with nausea.
  • Systemic Events: General reactions such as fever and a feeling of swelling of the entire body have been reported.

Serious Adverse Reactions and Risk Considerations

Certain serious adverse reactions are rare but documented in association with parenteral Cobalamin administration:

  • Anaphylaxis and Cardiovascular Events: Severe reactions such as anaphylactic shock and death, pulmonary edema, and congestive heart failure are noted. Cardiovascular events are specifically documented as occurring early in treatment.
  • Vascular Events: Peripheral vascular thrombosis is also listed as a serious vascular adverse reaction.
  • Specific Patient Groups: Caution is advised regarding use in patients with Leber's disease due to the risk of severe and swift optic atrophy. A formal contraindication exists for individuals sensitive to cobalt or any component of the medication.

Regulatory Safety Limitations

Regulatory documents include safety constraints, such as the note that indiscriminate B12 administration may mask the true diagnosis of B12 deficiency. Furthermore, the exclusive use of folic acid to treat B12-deficient megaloblastic anemia is associated with the risk of progressive and irreversible neurologic damage.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Adenosylcobalamin

Overdose scope

Documented overdose presentations: Non-specific toxicity is reported; the body's rapid renal excretion limits specific manifestations of overexposure.

Physiological systems affected (as stated in label): The Cardiovascular system may be affected (pulmonary edema, congestive heart failure, peripheral vascular thrombosis) and the Immune system (anaphylactic shock).

Dose-related or exposure-related factors (if applicable): Life-threatening outcomes are associated with parenteral administration.

Population-specific overdose notes (if applicable): None explicitly documented in the official regulatory sections.

Emergency-response statements (as written in official documents): Management relies on providing symptomatic and supportive treatment; no specific antidote is known.

When immediate medical help is required (label-derived phrasing only): Immediate medical attention is required upon observing signs of anaphylactic shock or acute cardiovascular complications.

Overdose classifications (high-level)

Severity classification (as defined in official documents): The risk is classified by the potential for life-threatening systemic reactions.

Regulatory basis (EMA / FDA / etc.): Information is derived from official FDA and NIH documents.

Overdose-context constraints (as defined in official documents): Hospital monitoring and observation are indicated to manage and stabilize severe complications.

Resulting overdose structure

Official overdose statements:

  • Non-specific toxicity is expected due to rapid renal excretion.
  • Life-threatening systemic reactions, including anaphylactic shock and death, have been documented with parenteral B12 compounds.
  • Management requires symptomatic and supportive treatment; no specific antidote is documented.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile primarily by the substance's low inherent toxicity and the corresponding physiological mechanism of rapid renal clearance of excess amounts. The necessity for immediate medical attention is mandated by the potential for rare, life-threatening systemic manifestations documented in official reports. Consequently, the officially described procedural steps focus on supportive treatment to manage these acute, severe presentations.

Therapeutic Uses of Adenosylcobalamin

What Adenosylcobalamin Treats: Main Uses and Benefits

Adenosylcobalamin (AdoCbl or Dibencozide), a bioactive coenzyme form of Vitamin B12, is commonly used to address the systemic effects of Cobalamin deficiency. This form is relevant for supporting hematological and neurological health.

The key therapeutic areas include managing Megaloblastic Anemia (e.g., Pernicious Anemia), supporting the nervous system in peripheral neuropathy and gait impairment, and serving as a replacement therapy in genetic metabolic disorders and chronic malabsorption syndromes.

This therapy is applied during periods of systemic imbalance, targeting symptoms such as chronic fatigue, profound weakness, and paresthesia (numbness/tingling). By supporting blood formation, this therapy addresses symptoms related to systemic imbalance, which helps improve day-to-day comfort.

“This therapy addresses chronic fatigue and profound systemic weakness, which may contribute to improved day-to-day comfort and stability.”

Quick Fact: Relief for Neuro-Sensory Symptoms

AdoCbl is relevant for easing challenging symptoms that create noticeable neurological strain, particularly those involving sensory disturbances and motor coordination issues linked to B12 deficiency. It is used to help manage symptoms like paresthesia and gait impairment, supporting patients when symptoms interfere with daily functioning, and may assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Adenosylcobalamin

Official regulatory documents strictly define the eligibility for Adenosylcobalamin (AdoCbl) use, primarily based on confirmed deficiency status and specific pre-existing conditions.

Populations Not Eligible (Contraindications)

Classification Population Restriction
Absolute Contraindication Individuals with known hypersensitivity or allergy to Cobalamins, Cobalt, or any excipients in the product formulation.
Disease-Specific Patients with early stages of Leber's disease (hereditary optic nerve atrophy) must not use this medicine.

Approved and Restricted Populations

Population Group Eligibility Status
Adults and Older Adults Use is established for the treatment of confirmed Cobalamin deficiency.
Pediatric Patients Use is generally established for B12 deficiency and specific inborn errors of metabolism.
Pregnant/Lactating Use is permitted to treat confirmed deficiency, as determined by medical necessity.
Anemia Etiology Not recommended for treating megaloblastic anemia until B12 deficiency is confirmed, to avoid masking coexisting folate deficiency.

Official labeling for oral forms indicates they are often too undependable for use in severe malabsorption disorders like pernicious anemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents identify several categories of medicinal products that can interfere with the activity or absorption of Vitamin B12 (Adenosylcobalamin). These interactions are primarily focused on reducing the availability or efficacy of the vitamin, rather than causing direct toxicity.

Key interacting product categories that require specific management include agents that reduce stomach acidity (such as Proton Pump Inhibitors and H2-receptor antagonists), antidiabetic agents (notably Metformin), and certain anticonvulsants (e.g., Phenytoin). These agents may reduce the intestinal absorption of Vitamin B12 or increase the body's metabolic requirements, necessitating close monitoring of B12 status during concurrent, long-term use.

Specific interacting agents where co-administration is often discouraged or restricted due to direct antagonism include:

  • Chloramphenicol: Can antagonize the blood cell-producing (hematopoietic) response to B12 therapy.
  • Nitrous oxide: Can functionally inactivate Vitamin B12 in the body, potentially leading to or worsening deficiency, especially during general anesthesia.

Regulatory constraints dictate that the risk of therapeutic failure (reduced efficacy) must be weighed against the need for the interacting medicine. For example, in cases of long-term interference with absorption, an alternative, non-oral route of B12 administration may be required.

Mechanism of Action

Coenzyme-Dependent Mitochondrial Activation

Adenosylcobalamin ( AdoCbl) functions as an essential cofactor for its primary target, the enzyme Methylmalonyl-CoA Mutase ( MCM), which operates within the mitochondrial matrix. This mechanism is a direct replacement/supply of a required molecular partner, enabling the enzyme to catalyze a critical isomerization reaction. Catalysis is initiated via the homolytic cleavage of the coenzyme's cobalt-carbon ( Co-C) bond, which starts a free-radical chemical sequence. This action contributes to the maintenance of cellular bioenergetics and metabolic stability.

Regulation of Metabolic Flux and Toxic Clearance

The AdoCbl- MCM complex is central to pathways regulating the catabolism of odd-chain fatty acids and several branched-chain amino acids. By efficiently converting L-Methylmalonyl-CoA to Succinyl-CoA, the mechanism prevents the upstream substrate from accumulating and hydrolyzing into the metabolite methylmalonic acid ( MMA). The resulting physiological effect is the reduction of toxic intermediate accumulation and the provision of Succinyl-CoA directly into the TCA cycle, which is essential for neuronal metabolic activity and homeostasis.

Mechanistic Limitation and Target Dependency

The functional effectiveness of this coenzyme replacement mechanism is strictly dependent on the integrity of the target enzyme. The mechanism is functionally constrained in biological scenarios where the Methylmalonyl-CoA Mutase ( MCM) enzyme is structurally absent or severely compromised due to genetic defects, preventing the available AdoCbl cofactor from binding or initiating catalysis.

Dosage and Administration Information

Administration Overview

Adenosylcobalamin is a bioactive form of Vitamin B12. The method of administration depends on the specific formulation provided, which typically includes oral, sublingual, or injectable options.

Formulations and Techniques

  • Sublingual Tablets and Liquids: These are designed to be placed under the tongue or held in the mouth. This method allows the compound to be absorbed directly through the mucosal membranes into the bloodstream, bypassing the digestive tract.
  • Oral Capsules and Tablets: These are swallowed and processed through the digestive system. For optimal absorption, these forms are often taken on an empty stomach or as directed by a healthcare professional.
  • Injectable Solutions: In certain clinical settings, adenosylcobalamin may be administered via intramuscular or subcutaneous injection. These procedures are typically performed by a healthcare provider or under specific medical supervision.

Timing and Consistency

To maintain stable levels of the vitamin in the body, it is common practice to use the supplement at the same time each day. Consistency is often emphasized to ensure the body has a steady supply of the active coenzyme for metabolic processes.

Storage and Handling

Adenosylcobalamin is sensitive to light and temperature. To maintain the integrity of the product:

  • Keep the supplement in its original container to protect it from light exposure.
  • Store at room temperature in a dry environment, away from excessive heat or moisture.
  • Ensure the container is tightly closed when not in use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adenosylcobalamin

Evidence for use in Major Depressive Disorder (MDD)

Adenosylcobalamin was studied for Major Depressive Disorder, a condition characterized by functional limitations and periods of heightened symptoms. Research examined this in the context of short-term (around 6-8 week) and intermediate-term (up to 6 months) randomized controlled trials (RCTs). These studies primarily included adult participants diagnosed with MDD, often including those with fluctuating symptoms. The measured outcomes included changes in standard symptom rating scales (like the HAM-D or MADRS) and assessments of daily functioning or activity level.

Studies reported measurements of symptom patterns observed in the studied populations during the short treatment periods. These trials reported measurements of symptom changes when comparing the studied substance to placebo. Studies also gathered data on participant discontinuation rates. Data show patterns related to measured shifts in these symptom scores, but findings were mixed regarding the magnitude of the measured changes across different trials.

Evidence for use in Generalized Anxiety Disorder (GAD)

Adenosylcobalamin was evaluated in research exploring outcomes related to Generalized Anxiety Disorder. The existing evidence is largely derived from short-term randomized controlled trials (typically 8 to 12 weeks). The research focused on measuring changes in standard anxiety rating scales (like the HAM-A) and assessed functional impairment scores. Studies reported specific measurements of anxiety severity scores compared to placebo groups over the acute study period.

What is Still Uncertain about Adenosylcobalamin Research

Research, so far, provides context but not individual predictions. Evidence highlights what is known — and what is still uncertain. The main uncertainties across all studied indications include the following: long-term outcomes are not fully established beyond the acute treatment phase; comparative evidence is lacking (meaning few studies directly compared this substance against other treatments); data for certain groups remain insufficient (such as children and older adults); and evidence quality varies across studies, sometimes presenting mixed findings regarding the measured changes. Research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Frequently Asked Questions (FAQ)

Common questions about Adenosylcobalamin (FAQ)

Q: What is Adenosylcobalamin?

Adenosylcobalamin is one of the two active forms of Vitamin B12 (cobalamin) naturally found in the body. It plays a critical role as a coenzyme in the mitochondria, primarily involved in the metabolism of fatty acids and amino acids, and the production of energy.

Q: How does Adenosylcobalamin differ from Cyanocobalamin?

Cyanocobalamin is a synthetic form of Vitamin B12 often used in supplements and fortified foods. It requires conversion in the body to become active, specifically into Methylcobalamin and Adenosylcobalamin. In contrast, Adenosylcobalamin is already a biologically active form and does not require this metabolic conversion step.

Q: What is the primary role of Adenosylcobalamin in the body?

Its primary role is in the methylmalonyl-CoA mutase enzyme reaction within the mitochondria. This is essential for the proper breakdown (catabolism) of certain fats and proteins. Deficiency in this pathway can lead to the accumulation of methylmalonic acid (MMA), which is a key marker for Vitamin B12 deficiency.

Q: Is Adenosylcobalamin used to treat B12 deficiency?

Yes, like other forms of Vitamin B12, it can be used to treat or prevent Vitamin B12 deficiency (cobalamin deficiency). Deficiency can result from inadequate intake or absorption issues, such as those caused by pernicious anemia or certain gastrointestinal disorders.

Q: Are there any common side effects of Adenosylcobalamin?

Vitamin B12 is generally considered safe and well-tolerated. Mild side effects are uncommon but may include headache, mild nausea, or diarrhea. Serious side effects are rare.

How should Adenosylcobalamin be stored and disposed of?

The storage and disposal of Adenosylcobalamin products are strictly governed by regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Item Requirement
Temperature Store at Controlled Room Temperature, defined as 15 C to 30 C (59 F to 86 F).
Protection The product must be protected from heat, light, and moisture to prevent degradation.
Child Safety It is a mandatory requirement to keep this product out of the reach of children.

Disposal and Waste Handling

Unused or expired product must be disposed of according to local regulations.

For injectable forms, used syringes and needles must not be discarded in household trash. Instead, they must be placed immediately in an FDA-cleared sharps disposal container or a designated heavy-duty plastic alternative.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Adenosylcobalamin found in:

A-Z Index: